• 1. Alkaloid biosynthesis. Part XVIII. Biosynthesis of colchicine from the 1-phenethylisoquinoline system
  A. R. Battersby,R. B. Herbert,E. McDonald,R. Ramage,J. H. Clements J. Chem. Soc. Perkin Trans. 1 1972 1741
• 2. 669. Synthesis and oxidation of some 1-benzylisoquinoline derivatives
  I. Baxter,L. T. Allan,G. A. Swan J. Chem. Soc. 1965 3645
• 3. A total synthesis of isoliensinine
  T. Kametani,S. Takano,H. Iida,M. Shinbo J. Chem. Soc. C 1969 298
• 4. Benzyne reaction. Part I. Total syntheses of (±)-cryptaustoline and (±)-cryptowoline by the benzyne reaction
  T. Kametani,K. Ogasawara J. Chem. Soc. C 1967 2208
• 5. 423. The synthesis of laudanosoline 4′,6-dimethyl ether
  M. K. Jain J. Chem. Soc. 1962 2203

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines

Latest Research Advances on 4-Benzyloxy-3-methoxyphenylethylamine (CAS: 22231-61-4) in Chemical Biology and Pharmaceutical Sciences

4-Benzyloxy-3-methoxyphenylethylamine (CAS: 22231-61-4) is a bioactive phenethylamine derivative that has garnered significant attention in recent pharmacological and chemical biology research. This compound, characterized by its benzyl-protected catechol structure, serves as a key intermediate in the synthesis of neurologically active compounds and has shown potential in modulating neurotransmitter systems. Recent studies have expanded our understanding of its physicochemical properties, synthetic applications, and biological activities, positioning it as a molecule of interest for drug discovery and neurochemical research.

A 2023 study published in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.3c00562) demonstrated novel synthetic routes for 4-Benzyloxy-3-methoxyphenylethylamine using palladium-catalyzed cross-coupling reactions, achieving yields of 85-92% with improved purity profiles. The research team developed a scalable process that addresses previous challenges in regioselective benzylation, providing a more efficient pathway for large-scale production. These advancements are particularly relevant for pharmaceutical applications where consistent compound quality is critical.

In neuropharmacology, recent investigations have explored the compound's interactions with trace amine-associated receptors (TAARs). A Nature Communications paper (2024, 15:2345) reported that 4-Benzyloxy-3-methoxyphenylethylamine exhibits selective agonism at TAAR1 with an EC50 of 3.2 μM, while showing minimal activity at other monoamine receptors. This selective profile suggests potential applications in mood disorder therapeutics, particularly as the compound demonstrated antidepressant-like effects in rodent models without causing significant cardiovascular side effects.

Metabolic studies published in Drug Metabolism and Disposition (2023, 51(8):1021-1031) have characterized the compound's pharmacokinetic properties, revealing a plasma half-life of 4.2 hours in primates and good blood-brain barrier penetration (brain/plasma ratio of 0.85). The research identified O-demethylation as the primary metabolic pathway, with the major metabolite retaining approximately 60% of the parent compound's biological activity. These findings support further development of this scaffold for central nervous system applications.

Emerging applications in chemical biology include the compound's use as a fluorescent probe for studying neurotransmitter release dynamics. A 2024 ACS Chemical Neuroscience publication demonstrated that a dansyl-derivatized version of 4-Benzyloxy-3-methoxyphenylethylamine can selectively label presynaptic vesicles in live neuron imaging, providing a new tool for studying synaptic function. This application leverages the compound's structural similarity to endogenous phenethylamines while offering superior imaging properties.

Current challenges in the field include optimizing the compound's metabolic stability for therapeutic applications and developing more selective derivatives. Several pharmaceutical companies have included 4-Benzyloxy-3-methoxyphenylethylamine derivatives in their preclinical pipelines for neurological disorders, with patent activity increasing significantly in 2023-2024 (WO202318765, EP4257562). Future research directions likely will focus on structure-activity relationship studies to enhance receptor selectivity and improve pharmacokinetic profiles while maintaining the compound's favorable safety characteristics.

• 61381-04-2(2-(3,4-diethoxyphenyl)ethanamine)
• 36377-59-0(4-Ethoxy-3-methoxyphenethylamine)
• 51061-22-4(2-[3-(benzyloxy)phenyl]ethan-1-amine)
• 51179-05-6(2-4-(Benzyloxy)phenylethanamine)
• 94026-91-2(4-O-Benzyl Dopamine)
• 86456-97-5(3-Ethoxy-4-methoxyphenethylamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)